CONTACT


    EFFICACY STUDY, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3, OF A HETEROLOGOUS VACCINATION REGIMEN OF AD26.MOS4.HIV AND CLADO C GP140 AND MOSAIC GP14 ADJUVANTED TO PREVENT HIV-1 INFECTION AMONG CISGENDER MEN AND TRANSGENDER INDIVIDUALS WHO HAVE SEX WITH CISGENDER MEN AND/OR TRANSGENDER INDIVIDUALS

    Objectives:

    1. Enroll and follow participants in protocol HVTN 706/HPX3002 in support of the protocol and in accordance with this Subaward.
    2. Comply with the HVTN protocol registration and activation process as outlined in this Subaward. Subrecipient

    CRS must receive an official activation notification of each protocol from HVTN Regulatory Affairs prior to a participant enrolling in the study.